Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors After Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinomas

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02547350

Enrollment

200

Registered

2015-09-11

Start date

2015-09-30

Completion date

Unknown

Last updated

2015-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Recurrence, Upper Tract Urothelial Carcinoma

Brief summary

The purpose of this study is to evaluate the efficacy of prophylactic intravesical chemotherapy (different chemotherapy drugs and dosage regimen) in the prevention of bladder recurrence after nephroureterectomy for upper tract urothelial carcinoma (UTUC).

Interventions

DRUGpharmorubicin or pirarubicin

pharmorubicin 50mg pirarubicin 30mg

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. Patients who were clinically diagnosed with UTUC 2. Treated with radical nephroureterectomy

Exclusion criteria

1. Distant metastasis 2. Prior history of bladder or synchronous bladder cancer 3. Administration of neoadjuvant chemotherapy 4. Presence of severe complications.

Design outcomes

Primary

Measure	Time frame
intravesical recurrence-free survival	two years after surgery

Secondary

Measure	Time frame
cancer-specific survival	two years after surgery

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026